SRZN | tickerfilter.com

Fundamental analysis

35%

Profitability 35%

Dept financing 43%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.24%

1 Month

9.11%

3 Months

38.11%

6 Months

118.11%

1 Year

188.44%

2 Year

222.39%

Key data

Stock price

$29.95

P/E Ratio

N/A

DAY RANGE

$27.01 - $30.67

EPS

-$48.27

52 WEEK RANGE

$5.90 - $33.96

52 WEEK CHANGE

$186.94

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

11.487 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

0.89

PUBLIC FLOAT

AVERAGE 10 VOLUME

$135,616

AVERAGE 30 VOLUME

$133,614

Company detail

CEO: Craig C. Parker
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

SRZN - Surrozen, Inc./DE